Page 109 - CIBEREHD2016-ENG

Most relevant scientific articles
• Robles-Campos R, Brusadin R, López-Conesa A, Parrilla P. Modified ALPPS Procedures Avoiding Division of Portal Pedicles. Ann Surg. 2017 Feb;265(2): e21
• Cascales-Campos PA, Sánchez-Fuentes PA, Gil J, Gil E, López-López V, Rodriguez Gomez-Hidalgo N, Fuentes D, Parrilla P. Effectiveness and failures of a fast track protocol after cytoreduction
and hyperthermic intraoperative intraperitoneal chemotherapy in patients with peritoneal surface malignancies. Surg Oncol. 2016 Dec;25(4):349-354
• Tyrkalska SD, Candel S, Angosto D, Gómez-Abellán V, Martín-Sánchez F, García-Moreno D, Zapata- Pérez R, Sánchez-Ferrer Á, Sepulcre MP, Pelegrín P, Mulero V. Neutrophils mediate Salmonella Typhimurium clearance through the GBP4 inflammasome-dependent production of prostaglandins. Nat Commun. 2016 Jul 1; 7:12077.
• de Torre-Minguela C, Barberà-Cremades M, Gómez AI, Martín-Sánchez F, Pelegrín P. Macrophage activation and polarization modify P2X7 receptor secretome influencing the inflammatory process. Sci Rep. 2016 Mar 3; 6:22586.
• Martínez-Bosch N, Fernández-Zapico ME, Navarro P, Yélamos J. Poly(ADP-Ribose) Polymerases: New Players in the Pathogenesis of Exocrine Pancreatic Diseases. Am J Pathol. 2016 Feb;186(2):234-41.
Hightlights
Our group is focus in five closely related research areas: Barrett oesophagus and the development of oesophagus adenocarcinoma, Inflammation and cancer, Poly(ADP-ribose) polymerases and cancer, Liver regeneration and liver tumour, and Liver transplantation. During 2016, we have continue to study the Barrett oesophagus stability after radiofrequency treatment and the identification of genetic alterations induced by this treatment. In relation with inflammation and cancer, we are studying the regulation
of inflammatory response to extracellular ATP and P2X7 receptor signalling: through and beyond the inflammasome. As a main achieve in this area, we have demonstrated that the NLRP3 inflammasome is released as a particulate danger signal, acting as an extracellular oligomeric complex, that amplifies the inflammatory response. In relation to the study play by Poly(ADP-ribose) polymerase enzymes in cancer, we are exploring the lethal interactions between PARP proteins and the DNA damage response in cancer treatment. Among the data obtained, we have demonstrated that PARP-1 plays a key role in pancreatic cancer. Recently, we have started a research focus in understanding the immunomodulatory role of PARP proteins and it implication in the immune response to tumours. Other achievements of our group are related to liver tumour and tumoral progression after portal occlusion in patients with liver resection in two times. Finally, we continue working in liver tolerance after liver transplant, aim to analysis immunological factors and gene expression profiles involved in liver tolerance.
EHD
research Groups 109